314 related articles for article (PubMed ID: 33121874)
1. Extinguishing the Embers: Targeting AML Metabolism.
Culp-Hill R; D'Alessandro A; Pietras EM
Trends Mol Med; 2021 Apr; 27(4):332-344. PubMed ID: 33121874
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism.
Farge T; Saland E; de Toni F; Aroua N; Hosseini M; Perry R; Bosc C; Sugita M; Stuani L; Fraisse M; Scotland S; Larrue C; Boutzen H; Féliu V; Nicolau-Travers ML; Cassant-Sourdy S; Broin N; David M; Serhan N; Sarry A; Tavitian S; Kaoma T; Vallar L; Iacovoni J; Linares LK; Montersino C; Castellano R; Griessinger E; Collette Y; Duchamp O; Barreira Y; Hirsch P; Palama T; Gales L; Delhommeau F; Garmy-Susini BH; Portais JC; Vergez F; Selak M; Danet-Desnoyers G; Carroll M; Récher C; Sarry JE
Cancer Discov; 2017 Jul; 7(7):716-735. PubMed ID: 28416471
[TBL] [Abstract][Full Text] [Related]
3. Targeting mitochondrial respiration for the treatment of acute myeloid leukemia.
Carter JL; Hege K; Kalpage HA; Edwards H; Hüttemann M; Taub JW; Ge Y
Biochem Pharmacol; 2020 Dec; 182():114253. PubMed ID: 33011159
[TBL] [Abstract][Full Text] [Related]
4. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
Polak A; Bialopiotrowicz E; Krzymieniewska B; Wozniak J; Stojak M; Cybulska M; Kaniuga E; Mikula M; Jablonska E; Gorniak P; Noyszewska-Kania M; Szydlowski M; Piechna K; Piwocka K; Bugajski L; Lech-Maranda E; Barankiewicz J; Kolkowska-Lesniak A; Patkowska E; Glodkowska-Mrowka E; Baran N; Juszczynski P
Cell Death Dis; 2020 Nov; 11(11):956. PubMed ID: 33159047
[TBL] [Abstract][Full Text] [Related]
5. High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34-positive AML.
Daga S; Rosenberger A; Quehenberger F; Krisper N; Prietl B; Reinisch A; Zebisch A; Sill H; Wölfler A
Cancer Med; 2019 Apr; 8(4):1771-1778. PubMed ID: 30848055
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia.
de Beauchamp L; Himonas E; Helgason GV
Leukemia; 2022 Jan; 36(1):1-12. PubMed ID: 34561557
[TBL] [Abstract][Full Text] [Related]
7. Lipids and the cancer stemness regulatory system in acute myeloid leukemia.
Lim INX; Nagree MS; Xie SZ
Essays Biochem; 2022 Sep; 66(4):333-344. PubMed ID: 35996953
[TBL] [Abstract][Full Text] [Related]
8. Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia.
de Figueiredo-Pontes LL; Pintão MC; Oliveira LC; Dalmazzo LF; Jácomo RH; Garcia AB; Falcão RP; Rego EM
Cytometry B Clin Cytom; 2008 May; 74(3):163-8. PubMed ID: 18200595
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells.
Jones CL; Stevens BM; D'Alessandro A; Reisz JA; Culp-Hill R; Nemkov T; Pei S; Khan N; Adane B; Ye H; Krug A; Reinhold D; Smith C; DeGregori J; Pollyea DA; Jordan CT
Cancer Cell; 2018 Nov; 34(5):724-740.e4. PubMed ID: 30423294
[TBL] [Abstract][Full Text] [Related]
10. Mitochondrial metabolism: powering new directions in acute myeloid leukemia.
Stubbins RJ; Maksakova IA; Sanford DS; Rouhi A; Kuchenbauer F
Leuk Lymphoma; 2021 Oct; 62(10):2331-2341. PubMed ID: 34060970
[TBL] [Abstract][Full Text] [Related]
11. Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells.
Larrue C; Guiraud N; Mouchel PL; Dubois M; Farge T; Gotanègre M; Bosc C; Saland E; Nicolau-Travers ML; Sabatier M; Serhan N; Sahal A; Boet E; Mouche S; Heydt Q; Aroua N; Stuani L; Kaoma T; Angenendt L; Mikesch JH; Schliemann C; Vergez F; Tamburini J; Récher C; Sarry JE
Nat Commun; 2021 Jan; 12(1):422. PubMed ID: 33462236
[TBL] [Abstract][Full Text] [Related]
12. TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells.
Kikushige Y; Miyamoto T
Int J Hematol; 2013 Dec; 98(6):627-33. PubMed ID: 24046178
[TBL] [Abstract][Full Text] [Related]
13. circFAM193B interaction with PRMT6 regulates AML leukemia stem cells chemoresistance through altering the oxidative metabolism and lipid peroxidation.
Yang X; Liu J; Liu W; Wu H; Wei Y; Guo X; Jia H; Can C; Wang D; Hu X; Ma D
Leukemia; 2024 May; 38(5):1057-1071. PubMed ID: 38424136
[TBL] [Abstract][Full Text] [Related]
14. Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells.
Pelosi E; Castelli G; Testa U
Blood Cells Mol Dis; 2015 Dec; 55(4):336-46. PubMed ID: 26460257
[TBL] [Abstract][Full Text] [Related]
15. Leukemic Stem Cells: From Leukemic Niche Biology to Treatment Opportunities.
Marchand T; Pinho S
Front Immunol; 2021; 12():775128. PubMed ID: 34721441
[TBL] [Abstract][Full Text] [Related]
16. Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine.
Buettner R; Nguyen LXT; Morales C; Chen MH; Wu X; Chen LS; Hoang DH; Hernandez Vargas S; Pullarkat V; Gandhi V; Marcucci G; Rosen ST
J Hematol Oncol; 2021 Apr; 14(1):70. PubMed ID: 33902674
[TBL] [Abstract][Full Text] [Related]
17. Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells.
Cook AM; Li L; Ho Y; Lin A; Li L; Stein A; Forman S; Perrotti D; Jove R; Bhatia R
Blood; 2014 May; 123(18):2826-37. PubMed ID: 24668492
[TBL] [Abstract][Full Text] [Related]
18. CD9, a potential leukemia stem cell marker, regulates drug resistance and leukemia development in acute myeloid leukemia.
Liu Y; Wang G; Zhang J; Chen X; Xu H; Heng G; Chen J; Zhao Y; Li J; Ni Y; Zhang Y; Shan J; Qian C
Stem Cell Res Ther; 2021 Jan; 12(1):86. PubMed ID: 33494824
[TBL] [Abstract][Full Text] [Related]
19. Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy.
Guo J; Russell EG; Darcy R; Cotter TG; McKenna SL; Cahill MR; O'Driscoll CM
Mol Pharm; 2017 Mar; 14(3):940-952. PubMed ID: 28146632
[TBL] [Abstract][Full Text] [Related]
20. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia.
Pollyea DA; Stevens BM; Jones CL; Winters A; Pei S; Minhajuddin M; D'Alessandro A; Culp-Hill R; Riemondy KA; Gillen AE; Hesselberth JR; Abbott D; Schatz D; Gutman JA; Purev E; Smith C; Jordan CT
Nat Med; 2018 Dec; 24(12):1859-1866. PubMed ID: 30420752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
